{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-006477","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2024-01-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.683224+00:00","generated_at":"2026-06-06T18:28:06.338999+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FDA delays YUTREPIA PDUFA date; PH-ILD amendment process ongoing","bullets":["FDA unable to issue action letter by Jan. 24, 2024 PDUFA date; no new goal date set.","No additional clinical data requested; FDA confirming process to add PH-ILD indication.","Federal Circuit upheld PTAB invalidity of '793 patent; '327 patent not subject to 30-month stay.","Company expects final approval after Tyvaso regulatory exclusivity expires March 31, 2024.","YUTREPIA already has tentative approval for PAH; quality, safety, efficacy standards met."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-006477","json":"https://secwatch.observer/filing/0001104659-24-006477.json","markdown":"https://secwatch.observer/filing/0001104659-24-006477.md","text":"https://secwatch.observer/filing/0001104659-24-006477.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924006477/0001104659-24-006477-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924006477/tm244104d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T18:28:06.338999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}